deficit in Medical Technology
Navigation Links
deficit in Medical Technology
... VYVANSE significantly improved
Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic ... (lisdexamfetamine dimesylate) (Attention deficit and
Hyperactivity Disorder ("ADHD")); the impact ...
... significant improvements in Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... for the treatment of the symptoms of Attention deficit Hyperactivity Disorder (ADHD). The data ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... prodrug stimulant for the treatment of Attention deficit Hyperactivity Disorder (ADHD), provided ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... study in pediatric patients with Attention deficit Hyperactivity Disorder (ADHD) showed the effect ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... in the market of VYVANSE(TM) (Attention deficit and Hyperactivity Disorder ("ADHD"); the impact ...
... system), the Attention deficit Hyperactivity Disorder (ADHD) patch, demonstrated ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... which demonstrated that adults with Attention deficit Hyperactivity Disorder (ADHD) experienced ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...
... trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment ... independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... 674,164 949,105 Total debt and lease financing 756,477 754,099 Total stockholders' deficit (241,375) (11,902) (c) Includes $69,360 and $70,931 in restricted investments at December 31, 2008 and December ...
... of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic ...
... significant improvements in Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... for the treatment of the symptoms of Attention deficit Hyperactivity Disorder (ADHD). The data ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... prodrug stimulant for the treatment of Attention deficit Hyperactivity Disorder (ADHD), provided ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... study in pediatric patients with Attention deficit Hyperactivity Disorder (ADHD) showed the effect ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... in the market of VYVANSE(TM) (Attention deficit and Hyperactivity Disorder ("ADHD"); the impact ...
... system), the Attention deficit Hyperactivity Disorder (ADHD) patch, demonstrated ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... which demonstrated that adults with Attention deficit Hyperactivity Disorder (ADHD) experienced ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
Methadone Frequently Causes Menopausal Symptoms in Young Women
... methadone dependent patients were self medicating pre-existing attention deficit disorders, anxiety and depression, with opiate pain pills. Many methadone patients need treatment for attention deficit disorders, insomnia, depression, anxiety and fatigue, in addition to ...Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
... (methylphenidate transdermal system) for the treatment of Attention deficit Hyperactivity Disorder (ADHD). A request from European regulators to ... needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and ...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
... liabilities 243 - Stockholders' deficit (10,458) (6,106) Total liabilities and stockholders' deficit $27,082 $ 28,092 ...... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...... trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment ... independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped ...
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
... liabilities 172 - Stockholders' deficit (20,143) (6,106) Total liabilities and stockholders' deficit $15,039 $28,092 ...Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... 1,317,577 1,312,796 Accumulated other comprehensive income 978 1,439 Accumulated deficit (1,187,966) (1,124,090) ---------- ---------- Total stockholders' ...... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
Spherix Reports First Quarter 2009 Earnings
... 80,438 shares, at cost at March 31, 2009 and December 31, 2008 (464,786) (464,786) Accumulated deficit (18,866,456) (16,800,372) ---------- ---------- Total ...BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
... Receivables from collaborations 9,847 11,982 Total assets 72,602 84,692 Accumulated deficit (258,560) (249,268) Stockholders' equity 38,517 46,426 Note 1: Derived from audited ...Bionovo Announces First Quarter 2009 Highlights and Financial Results
... paid-in capital 59,235 59,050 Accumulated other comprehensive gain 7 24 Accumulated deficit (44,118) (39,450) Total shareholders' equity 15,132 19,632 Total ...Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
... a four-week dose titration period followed by 24 weeks of treatment. Subjects were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program. About Obesity More than 300 million people worldwide and ...Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
... 44,923 30,492 Noncontrolling interest in Symphony Icon, Inc. 7,470 10,247 Accumulated deficit (508,955) (487,395) Total Lexicon Pharmaceuticals, Inc. stockholders' equity ...Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
... of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. Clonicel is the company's lead compound in a pipeline of products that ...... 674,164 949,105 Total debt and lease financing 756,477 754,099 Total stockholders' deficit (241,375) (11,902) (c) Includes $69,360 and $70,931 in restricted investments at December 31, 2008 and December ...
... of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic ...
Pharmasset Reports Fiscal Year End 2008 Financial Results
... Accumulated other comprehensive (loss) income (2,604) 4,405 Accumulated deficit (111,791,944) (57,134,233) Total stockholders' equity 35,187,345 ...SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
... 31, 2007, respectively 41,130 40,991 Additional paid-in capital 70,879,940 69,945,666 Accumulated deficit (61,050,605) (57,834,638) Total stockholders' equity 9,870,465 12,152,019 ...Other ContentshosthosthosthosthosthosthosthosthostinitiativeinitiativeinitiativeinitiativehybridhybridhybridhybridhybridhybridhybridhybridhumerushumerushumerusimmunityimmunityimmunityimmunityimmunityimmunityimmunityhumoralhumoralhumoralhybridomahybridomahydrogenhydrogenhydrogenhydrogenhydrogenhydrogenhydrogenhydrogenOther TagsVascoTipVascoScrewTendrilFinelineFlextendLigatureAccessories
(Date:11/6/2009)... To celebrate the 150th anniversary this month of ...merican Institute of Biological Sciences (AIBS) is... about Charles Darwin and his historic insights in...ian of the University of California, Berkeley, and...dian,s article, "Ten Myths About Charles Darwin," ...
(Date:11/6/2009)... PHILADELPHIA (November 06, 2009) The Monell Cent...o-hosts of the Beijing International Meeting on Ta...laboration with the CAS, the meeting will be the f...e held in China. , Alan Leshner, Chief Executive... of Science and Executive Publisher of Science mag...
(Date:11/5/2009)... Kent State University has been awarded a training... Science Foundation under its Integrative Graduati.... This is the first IGERT grant to be awarded to K...erican Recovery and Reinvestment Act of 2009, runs...t that focuses on environment aquatic resource sen...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Hospira Names Daphne E Jones Chief Information Officer 5611 1Hospira Names Daphne E Jones Chief Information Officer 5611 2Verizon Health Care Experts to Address 2009 Connected Health Symposium in Boston on Oct 21 59823 1Verizon Health Care Experts to Address 2009 Connected Health Symposium in Boston on Oct 21 59823 2Inverness Medical Innovations Schedules Conference Call for 10 3A00 a m ET October 27 2009 to Discuss Third Quarter 2009 Results 14544 1Inverness Medical Innovations Schedules Conference Call for 10 3A00 a m ET October 27 2009 to Discuss Third Quarter 2009 Results 14544 2(Date:11/9/2009)...ng is everybody,s buzz word today and for Recruite...nables Recruiters and Staffers create their own pr...nicate and close positions. The site also enables ...network with recruiters. , ...orces everyone to network more than ever and by th...
(Date:11/9/2009)...egained sexual function, study says, , ... were able to restore sexual function to rabbits w...n the lab and implanting it, a new study reports. ...earchers say the technique could one day be used t...We were able to show the tissue was able to integr...
(Date:11/9/2009)... may be too late when it comes to preventing or im...ub, Inc. (Take Off Pounds Sensibly), the nonprofit... (Vocus) November 9, 2009 -- Tomorrow m...oving a diabetes condition, according to TOPS Club...eight-loss support organization., , ,Diabetes is a...
(Date:11/9/2009)... Actress Mariska Hargitay and the ...on Saturday to raise awareness about the need for ...fornia by building healing and wellness kits for w... to give one to each of the estimated 600 women cu...s domestic violence shelters. ,, "Our goal is t...
(Date:11/9/2009)...USNewswire/ -- For the third consecutive year, the...ted the most preferred hospital for cancer care in...National Research Corporation. ,, (Logo: htt...LOGO ) ,, The annual survey was conducted thro...and August 2009. Survey respondents were the prima...
Breaking Medicine News(10 mins):Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year 2[0] Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals[0] Scientists Grow New Penile Tissue in the Lab[0] Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says[1] Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County[0] Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year
VascoTipVascoTwistVascoScrewCapSureEPICrystallineTendrilFinelineFlextendCapSureFixPhysiquePirouetLigatureAccessoriesTupos
Other Tagswheat 2integration 2integration 3rules 2rules 3flower 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |